CHICAGO -- (BUSINESS WIRE) -- Tempus AI, Inc. (NASDAQ: TEM) gab heute eine Verlängerung seines Datenlizenzvertrags mit Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) bekannt. Zusätzlich haben die beiden Unternehmen eine neue Vereinbarung getroffen, wonach Tempus Recursions RNA Foundation Model lizenzieren wird. Tempus und Recursion haben ihre mehrjährige Datenpartnerschaft bis November 2029 ver...
Genentech hat das erste Neurowissenschafts‑Target der Zusammenarbeit in ein gemeinsames Early‑Discovery‑Programm überführt und liefert damit erste Hinweise, dass Recursions Plattform neuartige, biologisch validierte Targets für die Arzneimittelentwicklung generieren kann REC-4881 (MEK1/2‑Inhibitor): Zusätzliche Phase‑2‑Daten zu Familiärer adenomatöser Polyposis (FAP) werden auf der Presidential...
Salt Lake City, UT, July 31, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on July 27, 2026, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 3,234,866 shares of its class A common stock in the aggregat...
Salt Lake City, UT, June 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in an upcoming investor conference: Goldman Sachs 47th Annual Global Healthcare Conference — Tuesday, June 9, 2026 Webcasts may be found in the events section of the Recursion Investor Relations we...
Salt Lake City, UT, May 29, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 2,991,840 shares of its class A common stock in the aggregate ...
Altitude Lab portfolio companies surpass $205M in funding as startups advance clinical trials, sign global pharma deals, and reshape early-stage biotech.
These high capital-intensity, asset-heavy companies offer a proven hedge against tech-market volatility.